Anifrolumab for heart and blood vessel health in lupus
Treatments studied
Part of Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests whether a drug called anifrolumab can improve early signs of heart and blood vessel damage in people with lupus. It may help prevent future heart problems and strokes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have a diagnosis of lupus.
- Your lupus medications must be stable for at least 4 weeks before the study and you must be on a low dose of steroids (prednisone 10 mg or less daily).
- You must have some early signs of blood vessel stiffness or inflammation, measured by special tests (like CAVI, PWV, or a PET scan).
- You must be up to date on COVID-19 and shingles vaccines, or have antibodies to these viruses.
- You must be willing to use effective birth control during the study and for 16 weeks after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new drug called anifrolumab can help treat lupus in people who haven't taken strong medications like biologics or immunosuppressants before. It looks at overall disease activity and the chance to reduce steroid use.
This trial tests anifrolumab, given as a shot under the skin or through a vein, to see how it works in people with lupus. It may help if you have active lupus symptoms and are on standard treatments.
This study looks at potential risks of the lupus medication anifrolumab in people with moderate to severe SLE. It focuses on serious infections and malignancies to see how safe the treatment is.
This study tracks how well anifrolumab works and how safe it is for people with active lupus. It's a real-world look at the drug's effects, so no additional treatments or tests are required beyond what your doctor already prescribes.
This study tests if a drug called anifrolumab can reduce severe fatigue in people with lupus. It is for adults whose lupus is under control but still feel very tired most days.
This study tests whether an intravenous medicine called anifrolumab can safely improve active systemic lupus (SLE) in children. If you qualify, you may receive the study treatment and be closely monitored for safety and lupus symptoms.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.